98013-97-9

Upstream product

• 98-79-3 L-Pyroglutamic acid 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 2899-60-7 Cbz-Gly-ONSuc 
• 1738-86-9 Z-Gly-ONp 
• 35418-16-7 L-t-butyl pyroglutamate 

Downstream Products

• 915958-49-5 dibenzyl-N-benzyloxycarbonylglycyl-L-pyroglutamyl-L-glutamate 
• 915958-48-4 tert-butyl-N-benzyloxycarbonylglycyl-L-pyroglutamic acid 

Relevant academic research and scientific papers

ANALOGS OF GLYCYL-PROLYL-GLUTAMATE

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson''s disease.

Synthesis and Pharmacology of the Potent Angiotensin-Converting Enzyme Inhibitor N--(S)-alanyl-(S)-pyroglutamic Acid

Structure 3a, a potent angiotensin-converting enzyme inhibitor, was prepared in five steps from L-(+)-α-amino-4-phenylbutyric acid by construction of the activated side-chain ester 16, displacement with L-pyroglutamate ester anion, and deblocking.Diastereomer separation was accomplished by chromatography at the diester stage, 17.Pharmacological assays established that 3a parallels enalapril in its ability to inhibit converting enzyme and lower blood pressure.